Kite Pharma, Inc. (KITE) is a publicly traded company in the Unknown sector. Across all available filings, 21 corporate insiders have executed 656 transactions totaling $204.8M, demonstrating a bearish sentiment with -$193.2M in net insider flow. The most recent transaction on Oct 3, 2017 involved a transaction of 159,329 shares valued at $28.7M.
No significant insider buying has been recorded for KITE in the recent period.
No significant insider selling has been recorded for KITE in the recent period.
Based on recent SEC filings, insider sentiment for KITE is bearish with an Insider Alignment Score of 3/100 and a net flow of -$193.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Kite Pharma, Inc. (KITE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 21 insiders are actively trading KITE stock, having executed 656 transactions in the past 90 days. The most active insider is Arie Belldegrun (Executive), who has made 22 transactions totaling $581.6M.
Get notified when executives and directors at KITE file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 3, 2017 | Belldegrun Arie | Executive | Disposition | 159,329 | $180.00 | $28.7M | Large |
| Oct 3, 2017 | Belldegrun Arie | Executive | Disposition | 500,000 | $180.00 | $90.0M | Large |
| Oct 3, 2017 | Belldegrun Arie | Executive | Disposition | 430,190 | $180.00 | $77.4M | Large |
| Oct 3, 2017 | Belldegrun Arie | Executive | Disposition | 500,000 | $180.00 | $90.0M | Large |
| Oct 3, 2017 | Belldegrun Arie | Executive | Disposition | 1,607,750 | $180.00 | $289.4M | Large |
| Oct 3, 2017 | Belldegrun Arie | Executive | Disposition | 159,160 | $N/A | $0 | |
| Oct 3, 2017 | M. Butitta Cynthia | Executive | Disposition | 93,667 | $N/A | $0 | |
| Oct 3, 2017 | D. Chang David | Executive | Tender | 16,605 | $180.00 | $3.0M | Large |
| Oct 3, 2017 | D. Chang David | Executive | Disposition | 38,675 | $N/A | $0 | |
| Oct 3, 2017 | L. Jenkinson Paul | Executive | Disposition | 9,462 | $N/A | $0 | |
| Oct 3, 2017 | L. Jenkinson Paul | Executive | Disposition | 3,000 | $180.00 | $540.0K | Large |
| Oct 3, 2017 | Susan Kim Helen | Executive | Tender | 4,193 | $180.00 | $754.7K | Large |
| Oct 3, 2017 | Susan Kim Helen | Executive | Disposition | 17,500 | $N/A | $0 | |
| Oct 3, 2017 | Wiezorek Jeffrey | Executive | Disposition | 11,150 | $N/A | $0 | |
| Oct 3, 2017 | Wiezorek Jeffrey | Executive | Tender | 14,674 | $180.00 | $2.6M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Disposition(D) | 30 | $588.7M | 65.6% |
Sale(S) | 392 | $199.0M | 22.2% |
Tender(U) | 13 | $77.1M | 8.6% |
Exercise(M) | 127 | $14.8M | 1.7% |
Other(J) | 3 | $12.6M | 1.4% |
Purchase(P) | 12 | $5.8M | 0.6% |
Gift(G) | 19 | $0 | 0.0% |
Award(A) | 48 | $0 | 0.0% |
Conversion(C) | 12 | $0 | 0.0% |
Insider selling pressure at Kite Pharma, Inc. has increased, with 21 insiders executing 656 transactions across all time. Total sales of $199.0M significantly outpace purchases of $5.8M, resulting in a net outflow of $193.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.